Shenzhen XtalPi Technology Co., Ltd. (“XtalPi,” stock code: 2228.HK) has signed a five-year strategic cooperation agreement, valued at approximately RMB 100 million, with PaiLin Bio-Pharmaceutical Co., Ltd. (“PaiLin Bio,” stock code: 000403), a leading player in the blood products sector. This partnership aligns with the “AI+” initiative to drive continuous innovation, accelerating the digital and intelligent transformation of the biopharmaceutical industry. By integrating XtalPi’s cutting-edge AI and robotic experimentation technologies with PaiLin Bio’s expertise in blood products, the collaboration aims to enhance the competitiveness of biopharmaceutical and specialized enterprises, fostering deep integration of AI with real-world industries.
The agreement, formalized at a signing ceremony attended by Dr. Wen Shuhao, Chairman of XtalPi, and Li Hao, Chairman of PaiLin Bio, focuses on three key areas:
- Drug Development and Optimization: Accelerating the R&D of blood products and other pharmaceuticals, shortening time-to-market, and reducing development costs.
- Intelligent Manufacturing and Quality Management: Providing comprehensive intelligent solutions for the full lifecycle of blood product production and quality control, including automation and AI applications in manufacturing processes, quality control labs, and testing.
- Protein Structure and Function Research: Conducting advanced studies on the functionality of existing plasma protein products and simulations of protein structures and functions in plasma to drive product upgrades and expand market applications.
PaiLin Bio is committed to becoming an industry-leading biotechnology company, guided by its vision of “Winning the Future with Intelligence.” Through this partnership, PaiLin Bio aims to accelerate product development, reduce R&D costs, unlock the potential of plasma protein products, and establish intelligent solutions for the full lifecycle of blood product production and quality management. This collaboration marks a new chapter in integrating AI with the blood products industry, driving technological innovation and high-quality development.
Since its inception, XtalPi has focused on overcoming the biopharmaceutical industry’s challenges of high costs, long timelines, and low success rates through the integration of AI, quantum physics, and robotic technologies. Recognizing that technology creates true value only when rooted in industry needs, XtalPi will leverage its intelligent and automated platform alongside PaiLin Bio’s industrialization expertise to form a closed-loop system, accelerating the development of innovative therapies.
About PaiLin Bio
PaiLin Bio-Pharmaceutical Co., Ltd. is a publicly listed company specializing in the research, development, production, and sales of blood products derived from healthy human plasma and specifically immunized plasma. Its products are critical strategic reserves and essential medicines for major diseases. The company operates two core subsidiaries: Guangdong Shuanglin, the largest blood products high-tech enterprise in Guangdong Province and a national “Specialized, Refined, Distinctive, and Innovative” (SRDI) small giant enterprise, and PaiSiFeiKe, the only blood products high-tech enterprise in Northeast China offering all three major product categories and a provincial SRDI enterprise. With 11 products and 38 plasma collection stations, PaiLin Bio ranks third in the industry for both product portfolio and plasma station network, positioning it as a leading player in the thousand-ton-scale blood products sector.
